Study of Metastatic Ocular Melanoma
Phase 2
- Conditions
- Ocular Melanoma
- Registration Number
- NCT00168870
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
This study evaluates treatment with combination versus monotherapy for patients with metastatic ocular melanoma.
- Detailed Description
Treatment of patients with metastatic ocular melanoma with combination chemotherapy Gemcitabine and Treosulfan versus monotherapy with Treosulfan as first-line chemotherapy.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Metastatic ocular melanoma
Exclusion Criteria
- Prior treatment with chemotherapy
- Active 2nd malignancy
- Cerebral metastasis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Determination of efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria
- Secondary Outcome Measures
Name Time Method Time to progression
Trial Locations
- Locations (1)
Hematology & Oncology Charité CBF Berlin
🇩🇪Berlin, Germany